O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+14.59%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$8.71B
AUM Growth
+$8.71B
(-8.1%)
Cap. Flow
-$1.43B
Cap. Flow
% of AUM
-16.47%
Top 10 Holdings %
Top 10 Hldgs %
33.55%
Holding
149
New
15
Increased
27
Reduced
39
Closed
13
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$130M |
| 2 |
Edwards Lifesciences
EW
|
$104M |
| 3 |
Merck
MRK
|
$99.3M |
| 4 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$85.5M |
| 5 |
Exelixis
EXEL
|
$79.4M |
Top Sells
| 1 |
HCA Healthcare
HCA
|
$211M |
| 2 |
Bristol-Myers Squibb
BMY
|
$155M |
| 3 |
AbbVie
ABBV
|
$148M |
| 4 |
Boston Scientific
BSX
|
$141M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
$137M |
Sector Composition
| 1 | Healthcare | 93.45% |
| 2 | Financials | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Bristol-Myers Squibb
BMY
$96.7B
| $118M | 1.34% |
2,187,400
-2,868,200
| -57% | -$155M |
|
27
BioMarin Pharmaceuticals
BMRN
$11.3B
| $107M | 1.21% |
1,151,900
-366,600
| -24% | -$33.9M |
|
|
ACHN
28
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $106M | 1.21% |
13,107,200
+1,425,600
| +12% | +$11.5M |
|
|
ESRX
29
DELISTED
Express Scripts Holding Company
ESRX
| $102M | 1.17% |
1,451,900
-246,700
| -15% | -$17.4M |
|
30
Johnson & Johnson
JNJ
$429B
| $101M | 1.15% |
858,000
+80,400
| +10% | +$9.5M |
|
|
31
HCA Healthcare
HCA
$95.4B
| $99.2M | 1.13% |
1,312,200
-2,786,100
| -68% | -$211M |
|
|
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
| $95.7M | 1.09% |
14,179,900
+3,206,000
| +29% | +$21.6M |
|
33
Zimmer Biomet
ZBH
$20.8B
| $93.3M | 1.06% |
717,500
-145,000
| -17% | -$18.9M |
|
34
Neurocrine Biosciences
NBIX
$13.5B
| $91.9M | 1.05% |
1,815,474
| – | – |
|
35
Illumina
ILMN
$15.2B
| $90M | 1.03% |
495,500
-350,700
| -41% | -$63.7M |
|
|
IPXL
36
DELISTED
Impax Laboratories, Inc.
IPXL
| $89.8M | 1.02% |
3,787,500
-2,099,200
| -36% | -$49.8M |
|
37
Corvus Pharmaceuticals
CRVS
$419M
| $88.5M | 1.01% |
5,379,349
| – | – |
|
38
UnitedHealth
UNH
$279B
| $85.7M | 0.98% |
611,800
-596,400
| -49% | -$83.5M |
|
|
BOLD
39
DELISTED
Audentes Therapeutics, Inc
BOLD
| $85.5M | 0.97% |
+4,801,638
| New | +$85.5M |
|
40
Teva Pharmaceuticals
TEVA
$21.5B
| $84.3M | 0.96% |
1,831,400
-928,400
| -34% | -$42.7M |
|
41
Glaukos
GKOS
$5.42B
| $82.3M | 0.94% |
2,180,000
-717,938
| -25% | -$27.1M |
|
|
MNK
42
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $81.7M | 0.93% |
1,170,200
-138,800
| -11% | -$9.69M |
|
|
BLUE
43
DELISTED
bluebird bio
BLUE
| $80.4M | 0.92% |
1,185,800
| – | – |
|
|
44
Exelixis
EXEL
$9.95B
| $79.4M | 0.9% |
+6,206,300
| New | +$79.4M |
|
45
Insmed
INSM
$30.3B
| $76.2M | 0.87% |
5,251,100
+1,092,500
| +26% | +$15.9M |
|
46
Humana
HUM
$37.5B
| $74.9M | 0.85% |
423,500
+83,800
| +25% | +$14.8M |
|
|
EGRX
47
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $72.5M | 0.83% |
1,036,100
| – | – |
|
|
AGN.PRA
48
DELISTED
Allergan plc.
AGN.PRA
| $72.5M | 0.83% |
+88,200
| New | +$72.5M |
|
49
Medtronic
MDT
$118B
| $66.2M | 0.75% |
766,600
+100,301
| +15% | +$8.67M |
|
|
INSY
50
DELISTED
Insys Therapeutics, Inc.
INSY
| $64.9M | 0.74% |
5,502,240
+814,000
| +17% | +$9.6M |
|